Richardson, P. G. Et Al. 2022. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. EUROPEAN JOURNAL OF HAEMATOLOGY , vol.108, no.1 , 73-83.

Richardson, P. G., Schjesvold, F., Weisel, K., Moreau, P., Anderson, L. D., White, D., ... Rodriguez-Otero, P.(2022). Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. EUROPEAN JOURNAL OF HAEMATOLOGY , vol.108, no.1, 73-83.

Richardson, Paul Et Al. "Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics," EUROPEAN JOURNAL OF HAEMATOLOGY , vol.108, no.1, 73-83, 2022

Richardson, Paul G. Et Al. "Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics." EUROPEAN JOURNAL OF HAEMATOLOGY , vol.108, no.1, pp.73-83, 2022

Richardson, P. G. Et Al. (2022) . "Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics." EUROPEAN JOURNAL OF HAEMATOLOGY , vol.108, no.1, pp.73-83.

@article{article, author={Paul G. Richardson Et Al. }, title={Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics}, journal={EUROPEAN JOURNAL OF HAEMATOLOGY}, year=2022, pages={73-83} }